申请人:Bristol-Myers Squibb Company
公开号:US05362879A1
公开(公告)日:1994-11-08
A novel series of oxazole derivatives having the Formulae I and II ##STR1## wherein R is H or C.sub.1 -C.sub.5 lower alkyl, X is N or CH, Y is H or CO.sub.2 R.sup.1, or CO.R.sup.2, provided that when X is CH, Y is not H, R.sup.1 is C.sub.1 -C.sub.5 lower alkyl, or phenylmethyl, and R.sup.2 is C.sub.1 -C.sub.5 alkyl; ##STR2## wherein R is H or C.sub.1 -C.sub.5 lower alkyl, X is (CH.sub.2).sub.n or para or meta substituted phenyl wherein the substituent is OR.sup.2, R.sup.2 is C.sub.1 -C.sub.5 alkyl, and n is an integer of 4 to 8, or a pharmaceutically acceptable salt thereof. The compounds are useful as inhibitors of ADP-induced blood platelet aggregation in human platelet-rich plasma.
一系列新颖的噁唑衍生物具有公式I和II,其中R是氢或C.sub.1-C.sub.5低级烷基,X是N或CH,Y是H或CO.sub.2R.sup.1或CO.R.sup.2,但当X是CH时,Y不是H,R.sup.1是C.sub.1-C.sub.5低级烷基或苯甲基,R.sup.2是C.sub.1-C.sub.5烷基;公式II中,R是氢或C.sub.1-C.sub.5低级烷基,X是(CH.sub.2).sub.n或对位或间位取代的苯基,其中取代基是OR.sup.2,R.sup.2是C.sub.1-C.sub.5烷基,n是4至8的整数,或其药学上可接受的盐。这些化合物可用作人血小板富集血浆中ADP诱导的血小板聚集的抑制剂。